U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024 04:00 ET | Alvotech
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....
82% Of States Suspen
82% Of States Suspend Medicaid Benefits For Incarcerated Populations: OPEN MINDS Releases Update On Inmate Medicaid Benefits
February 24, 2020 12:08 ET | Open Minds
Gettysburg, Pa, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A new report by OPEN MINDS, State Policy On Medicaid Benefits For State Prison Inmates: A State-By-State Review, found that 42 states (82%) suspend,...